What Happened

Ofichem, a Netherlands-based CDMO, has announced the acquisition of Kinentia Biosciences, a New York-based drug substance CDMO. The deal gives Ofichem an operational foothold in the US and adds Kinentia's early-stage development expertise to its European capabilities. The transaction is pending CFIUS approval and other closing conditions.

Who Is Affected

Kinentia customers will now gain access to Ofichem's wider Drug Substance network, including process scale-up, regulatory support, and GMP manufacturing at the FDA-inspected Ter Apel facility in the Netherlands. Ofichem's existing US and biotechnology customers benefit from increased flexibility in manufacturing location across the US and Europe.

Market Impact

This acquisition consolidates the CDMO space and highlights industry trends toward supply chain resilience and onshoring. The combined entity can support programs from early development through commercial manufacturing, reducing handover risks between independent providers.

• US Expansion: Oficohem gains a direct US presence, potentially attracting more domestic biotech clients seeking onshore manufacturing.
• Service Continuity: Customers get a single accountable organisation from early-stage to commercial, improving continuity.
• Regulatory opportunity: Ofichem's intent to explore US controlled-substance capabilities signals future needs for regulatory consulting and licencing support.

What to Watch

Monitor CFIUS approval, which is a condition for closing. After closure, watch integration of Kinentia into Oficohem's brand and operational network, as well as any further expansion plans for US controlled-substance capabilities that may create new compliance and consulting demands.

Related coverage

• Viatris to acquire Pacira BioSciences for $1.65B
• GE HealthCare to acquire Sofie Biosciences for $945M
• Shionogi acquires Texas-based rare disease biotech IntraBio for $2B
• Lundbeck reportedly seeks to acquire US pharma company Xeris Biopharma